174 related articles for article (PubMed ID: 10528174)
1. Presence of CpG DNA and the local cytokine milieu determine the efficacy of suppressive DNA vaccination in experimental autoimmune encephalomyelitis.
Lobell A; Weissert R; Eltayeb S; Svanholm C; Olsson T; Wigzell H
J Immunol; 1999 Nov; 163(9):4754-62. PubMed ID: 10528174
[TBL] [Abstract][Full Text] [Related]
2. Suppressive DNA vaccination in myelin oligodendrocyte glycoprotein peptide-induced experimental autoimmune encephalomyelitis involves a T1-biased immune response.
Lobell A; Weissert R; Eltayeb S; de Graaf KL; Wefer J; Storch MK; Lassmann H; Wigzell H; Olsson T
J Immunol; 2003 Feb; 170(4):1806-13. PubMed ID: 12574345
[TBL] [Abstract][Full Text] [Related]
3. Combined nasal administration of encephalitogenic myelin basic protein peptide 68-86 and IL-10 suppressed incipient experimental allergic encephalomyelitis in Lewis rats.
Xu LY; Yang JS; Huang YM; Levi M; Link H; Xiao BG
Clin Immunol; 2000 Sep; 96(3):205-11. PubMed ID: 10964538
[TBL] [Abstract][Full Text] [Related]
4. Suppressive immunization with DNA encoding a self-peptide prevents autoimmune disease: modulation of T cell costimulation.
Ruiz PJ; Garren H; Ruiz IU; Hirschberg DL; Nguyen LV; Karpuj MV; Cooper MT; Mitchell DJ; Fathman CG; Steinman L
J Immunol; 1999 Mar; 162(6):3336-41. PubMed ID: 10092787
[TBL] [Abstract][Full Text] [Related]
5. Experimental autoimmune encephalomyelitis in Lewis rats: IFN-beta acts as a tolerogenic adjuvant for induction of neuroantigen-dependent tolerance.
Mannie MD; Abbott DJ; Blanchfield JL
J Immunol; 2009 May; 182(9):5331-41. PubMed ID: 19380780
[TBL] [Abstract][Full Text] [Related]
6. Protective DNA vaccination against organ-specific autoimmunity is highly specific and discriminates between single amino acid substitutions in the peptide autoantigen.
Weissert R; Lobell A; de Graaf KL; Eltayeb SY; Andersson R; Olsson T; Wigzell H
Proc Natl Acad Sci U S A; 2000 Feb; 97(4):1689-94. PubMed ID: 10677519
[TBL] [Abstract][Full Text] [Related]
7. Impaired autoimmune T helper 17 cell responses following DNA vaccination against rat experimental autoimmune encephalomyelitis.
Andersson A; Isaksson M; Wefer J; Norling A; Flores-Morales A; Rorsman F; Kämpe O; Harris RA; Lobell A
PLoS One; 2008; 3(11):e3682. PubMed ID: 18997868
[TBL] [Abstract][Full Text] [Related]
8. Exquisite peptide specificity of oral tolerance in experimental autoimmune encephalomyelitis.
Javed NH; Gienapp IE; Cox KL; Whitacre CC
J Immunol; 1995 Aug; 155(3):1599-605. PubMed ID: 7543526
[TBL] [Abstract][Full Text] [Related]
9. Long-lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C-C chemokines.
Youssef S; Wildbaum G; Maor G; Lanir N; Gour-Lavie A; Grabie N; Karin N
J Immunol; 1998 Oct; 161(8):3870-9. PubMed ID: 9780152
[TBL] [Abstract][Full Text] [Related]
10. Prevention of experimental autoimmune encephalomyelitis by MIP-1alpha and MCP-1 naked DNA vaccines.
Youssef S; Wildbaum G; Karin N
J Autoimmun; 1999 Aug; 13(1):21-9. PubMed ID: 10441164
[TBL] [Abstract][Full Text] [Related]
11. Immunostimulatory CpG-modified plasmid DNA enhances IL-12, TNF-alpha, and NO production by bovine macrophages.
Shoda LK; Kegerreis KA; Suarez CE; Mwangi W; Knowles DP; Brown WC
J Leukoc Biol; 2001 Jul; 70(1):103-12. PubMed ID: 11435492
[TBL] [Abstract][Full Text] [Related]
12. Intrasplenic electro-transfer of IL-4 encoding plasmid DNA efficiently inhibits rat experimental allergic encephalomyelitis.
Ho SH; Lee HJ; Kim DS; Jeong JG; Kim S; Yu SS; Jin Z; Kim S; Kim JM
Biochem Biophys Res Commun; 2006 May; 343(3):816-24. PubMed ID: 16564024
[TBL] [Abstract][Full Text] [Related]
13. T cell receptor peptide therapy for autoimmune encephalomyelitis: stronger immunization is necessary for effective vaccination.
Matsumoto Y; Tsuchida M; Hanawa H; Abo T
Cell Immunol; 1994 Feb; 153(2):468-78. PubMed ID: 8118876
[TBL] [Abstract][Full Text] [Related]
14. Immunostimulatory DNA as a vaccine adjuvant.
Higgins D; Marshall JD; Traquina P; Van Nest G; Livingston BD
Expert Rev Vaccines; 2007 Oct; 6(5):747-59. PubMed ID: 17931155
[TBL] [Abstract][Full Text] [Related]
15. Induction of resistance to active experimental allergic encephalomyelitis by myelin basic protein-specific Th2 cell lines generated in the presence of glucocorticoids and IL-4.
Ramírez F; Mason D
Eur J Immunol; 2000 Mar; 30(3):747-58. PubMed ID: 10741389
[TBL] [Abstract][Full Text] [Related]
16. Discovery of immunostimulatory CpG-DNA and its application to tuberculosis vaccine development.
Yamamoto S; Yamamoto T; Nojima Y; Umemori K; Phalen S; McMurray DN; Kuramoto E; Iho S; Takauji R; Sato Y; Yamada T; Ohara N; Matsumoto S; Goto Y; Matsuo K; Tokunaga T
Jpn J Infect Dis; 2002 Apr; 55(2):37-44. PubMed ID: 12082305
[TBL] [Abstract][Full Text] [Related]
17. Critical requirement for aspartic acid at position 82 of myelin basic protein 73-86 for recruitment of V beta 8.2+ T cells and encephalitogenicity in the Lewis rat.
Smeltz RB; Wauben MH; Wolf NA; Swanborg RH
J Immunol; 1999 Jan; 162(2):829-36. PubMed ID: 9916705
[TBL] [Abstract][Full Text] [Related]
18. Contribution of CpG motifs to the immunogenicity of DNA vaccines.
Klinman DM; Yamshchikov G; Ishigatsubo Y
J Immunol; 1997 Apr; 158(8):3635-9. PubMed ID: 9103425
[TBL] [Abstract][Full Text] [Related]
19. Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides.
Fontoura P; Garren H; Steinman L
Int Rev Immunol; 2005; 24(5-6):415-46. PubMed ID: 16318989
[TBL] [Abstract][Full Text] [Related]
20. Plasmid interleukin-23 (IL-23), but not plasmid IL-27, enhances the protective efficacy of a DNA vaccine against Mycobacterium tuberculosis infection.
Wozniak TM; Ryan AA; Triccas JA; Britton WJ
Infect Immun; 2006 Jan; 74(1):557-65. PubMed ID: 16369012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
